Treating refractive disorders by targeting peroxisome proliferator-activated receptor (PPAR) signaling pathway
View Patent ↗A pharmacologic treatment of refractive disorders, specifically myopia or hyperopia, by targeting the PPAR signaling pathway using a PPARγ agonist without any binding to PPARα. It is demonstrated that the PPARγ agonist modulates ocular growth through therapeutic intervention at the protein level of the PPAR signaling pathway. The effectiveness of the PPARγ agonist in regulating the PPAR signaling pathway and its associated proteins, as evidenced by experiments using a lens-induced myopia (LIM) animal model. More particularly, it is also demonstrated that the pharmacological reduction of myopic eye growth in terms of biometrics with dosage effect through the administration of the PPARγ agonist.
1 . A method of treating a refractive disorder, comprising administering a PPARγ agonist, wherein the PPARγ agonist selectively binds to PPARγ without any binding to PPARα, and wherein the PPARγ agonist is rosiglitazone or a pharmaceutically acceptable salt thereof.
2 . The method of claim 1 , wherein the refractive disorder is selected from myopia or hyperopia.
3 . The method of claim 1 , further comprising administering a pharmaceutically acceptable addition.
4 . The method of claim 3 , wherein the pharmaceutically acceptable addition comprises an excipient, a stability additive, a carrier, a diluent, or a solubilizer.
5 . The method of claim 1 , wherein the administration of the PPARγ agonist being an administration form of that enables delivery to the patient's retina through the cornea and/or the blood-retinal barrier.
6 . The method of claim 5 , wherein the administration form is selected from an immediate-release form or a controlled-release form.
7 . The method of claim 6 , wherein the administration form comprises an injection form, an eye drop form, an eye ointment form, a hydrogel form, an ultrasonic ocular drug delivery form, and a drug-loaded contact lenses form.